ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models - Test2 - elhamkhani - TriplyDB

ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models

ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models

http://www.wikidata.org/entity/Q24628845

about

The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice Infectivity versus Seeding in Neurodegenerative Diseases Sharing a Prion-Like Mechanism Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain Apolipoproteins E and J interfere with amyloid-beta uptake by primary human astrocytes and microglia in vitro Impact of apolipoprotein E on Alzheimer's disease Mechanisms of Aβ Clearance and Degradation by Glial Cells APOE genotype and stress response - a mini review Regulation of the Postsynaptic Compartment of Excitatory Synapses by the Actin Cytoskeleton in Health and Its Disruption in Disease A Unified Hypothesis of Early- and Late-Onset Alzheimer's Disease Pathogenesis Vasculoprotection as a Convergent, Multi-Targeted Mechanism of Anti-AD Therapeutics and Interventions The low-density lipoprotein receptor-related protein 1 and amyloid-β clearance in Alzheimer's disease Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines.Genetic heterogeneity in Alzheimer disease and implications for treatment strategies The genetics and neuropathology of Alzheimer's disease Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases Proteolytic cleavage of apolipoprotein E4 as the keystone for the heightened risk associated with Alzheimer's disease Cortical odor processing in health and disease Regulation of the nongenomic actions of retinoid X receptor-α by targeting the coregulator-binding sites Improving the predictive value of interventional animal models data Embryonic Medaka Model of Microglia in the Developing CNS Allowing In Vivo Analysis of Their Spatiotemporal Recruitment in Response to Irradiation Thiazolidinediones promote axonal growth through the activation of the JNK pathway Genome-wide analysis of miRNA signature in the APPswe/PS1ΔE9 mouse model of alzheimer's disease Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology Presumed LRP1-targeting transport peptide delivers β-secretase inhibitor to neurons in vitro with limited efficiency A natural-product switch for a dynamic protein interface (11)C[double bond, length as m-dash]O bonds made easily for positron emission tomography radiopharmaceuticals Towards Personalized Intervention for Alzheimer's Disease ACAT1/SOAT1 as a therapeutic target for Alzheimer's disease Current and future implications of basic and translational research on amyloid-β peptide production and removal pathways On the central role of brain connectivity in neurodegenerative disease progression Alzheimer's disease: Unique markers for diagnosis & new treatment modalities Neuroinflammation in Alzheimer's disease Advances in drug design with RXR modulators Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy Interactions between inflammation, sex steroids, and Alzheimer's disease risk factors Gene Ontology and KEGG Pathway Enrichment Analysis of a Drug Target-Based Classification System Early Treatment Critical: Bexarotene Reduces Amyloid-Beta Burden In Silico Effect of LXR/RXR agonism on brain and CSF Aβ40 levels in rats Comment on "ApoE-Directed Therapeutics Rapidly Clear -Amyloid and Reverse Deficits in AD Mouse Models"Genome-wide association study of Alzheimer's disease

P2860

Q21195685-E21FF154-9142-4F6D-9A31-6A71E2C4DB83 Q21284823-B86981EE-823C-4DB5-96B5-C7481EBABCEF Q24308258-CFA3BC66-B9F1-4974-A03A-44917B416112 Q24321663-3F407EDF-B59B-4BC8-9E60-302D5EDC36B7 Q24567759-15CA539D-23BD-49D9-82C0-EA581228D176 Q26741609-052FEBC7-D121-41FB-B5A9-48651601FE33 Q26741633-569B694A-5C15-4FE2-A5F8-D34D5AAA19AD Q26748973-0A7C3477-5DBF-4CD2-A825-EF5A40809614 Q26781496-69264BA7-D165-4771-ADA7-29921FD177EC Q26781557-2D124E02-C2B9-4A7C-A2FF-5A410C5BAD7B Q26827353-33122E83-EB90-4262-B4D8-B4F8F57C3DEF Q26858963-A62CBC8E-6885-4E86-8038-726C78C344B6 Q26995802-8B342218-F2F0-44D1-AE8E-43E1F5FDBC0A Q26998097-23A4E4D2-F044-4E08-A873-072105671922 Q27009984-E66721D4-9A5C-4F63-91CE-0D04282EA132 Q27011311-8E090CC1-5F2C-4297-BC32-88C1C6168005 Q27024894-0143B483-88D8-45A8-97A9-7856892A8D35 Q27025972-E841F56C-163D-4DDC-8508-8B795E25A146 Q27026822-05CE7DE5-9292-4420-8B31-24C347631D15 Q27306763-86C3A7F0-691F-41D1-A406-834979D3D05B Q27317282-F90A6CCA-1BDE-4F51-A121-E3BA9A15FACC Q27320372-3DB1475B-32F7-44B6-86D0-084510F76DCB Q27327835-978E1604-F477-474E-A930-D4BF8273A4D3 Q27341864-70776DE7-E7ED-4E7E-9E1B-BB5690C5BFB5 Q27690221-405176EC-44DF-4793-A08C-6E4297E63FD1 Q28066107-A085C675-D7C4-4FEE-A4A5-AF3A0BD4E804 Q28080098-AFBFE5DE-04E1-4230-BF63-DFE8ED530722 Q28081654-342B9627-D2AB-459C-BDE2-BAA35E0DF14F Q28081678-1E420BFF-4777-4252-A087-2F04E7454478 Q28083682-B03BB607-EC50-48A7-8FF0-439810FD7C94 Q28085139-D0D04DA3-3E6D-473A-8610-2D44B4A7DE42 Q28259238-88047603-89BE-481A-B907-8135B52AB507 Q28274388-B7B87495-1B80-4BF3-BCCC-F143F537E079 Q28282855-6E50AA4B-1793-45D6-B1A9-7A3E9F103F77 Q28394967-71DB88DD-F116-4D17-9B43-D01DDFCC340F Q28547097-8D83A70C-3009-4E12-9455-B4BBDCD148D5 Q28551351-69F37DDE-CC1C-4856-821F-A5F1903627CC Q28602802-201AF363-BAF6-42AD-A0A2-FB5138608D12 Q29013008-CCDE94B6-D7A2-4818-8548-129D93E0AACF Q29417071-FE107FE7-2759-44E4-8137-F462104660AA

P2860

ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models

http://www.wikidata.org/entity/Q24628845

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

ApoE-directed therapeutics rap ...... se deficits in AD mouse models

@ast

ApoE-directed therapeutics rap ...... se deficits in AD mouse models

@en

ApoE-directed therapeutics rap ...... se deficits in AD mouse models

@nl

type

label

ApoE-directed therapeutics rap ...... se deficits in AD mouse models

@ast

ApoE-directed therapeutics rap ...... se deficits in AD mouse models

@en

ApoE-directed therapeutics rap ...... se deficits in AD mouse models

@nl

prefLabel

ApoE-directed therapeutics rap ...... se deficits in AD mouse models

@ast

ApoE-directed therapeutics rap ...... se deficits in AD mouse models

@en

ApoE-directed therapeutics rap ...... se deficits in AD mouse models

@nl

P1433

Q24628845-59B32443-3E9E-4A60-A029-CEA03278DC71

P1476

Q24628845-603FE67E-141A-4586-A70F-196423F66FBF

P2093

Q24628845-044A2052-A27D-4FC4-908A-EF0CC2789C45

Q24628845-0EFE5F3E-37F0-401B-8421-6795751AC2CB

Q24628845-227AAC2E-8094-49B1-8E7D-09C0E13FC6B7

Q24628845-587A3388-10CE-4355-AF47-58155A01E70A

Q24628845-711AC2D5-8035-471E-9841-6BC70BC1B76D

Q24628845-905259E3-FEDD-41F4-9F55-C13354D853A6

Q24628845-9D72E749-FD0C-47FC-8ED3-2E35F37BE0DC

Q24628845-CB74F2DD-7845-4879-B95A-7DDFBB69B224

Q24628845-D531871C-616E-4258-9D9D-470329EDD6C9

Q24628845-D619B5BD-7BBF-4D11-AF5B-337FBF51F647

P2860

Q24628845-0201F56E-7D0D-465F-9E02-071998E0022C

Q24628845-04D8E14D-74EC-40D8-9E6B-9F9468D9838D

Q24628845-06C1F8E1-C64F-474A-BE7F-5958D1A4522E

Q24628845-07A99FB2-6B00-45C6-ABC4-C6FF14F60FCE

Q24628845-0F12825A-F67B-4604-BC61-DCB133D38FB1

Q24628845-1F69EBBA-DE80-4772-82E4-7A4329DE762D

Q24628845-2CDA3CED-C4E2-4624-8AA8-5EFEFA036D11

Q24628845-2EA4669D-102E-4572-8272-35027AA8BC54

Q24628845-32229E0C-991D-47FF-91AE-FAF5EEA98DA9

Q24628845-36AEDB0A-B01F-4831-A1CA-716D675BB500

P304

Q24628845-9A708B27-8D4D-4A31-8853-BF7C759B8265

P31

Q24628845-E92550CA-CA8D-4D9D-AC02-D8E25F5470AE

P3181

Q24628845-694D25DB-4B4B-4FAF-8C4F-71215E288456

P356

Q24628845-ABE60B4E-9334-4C42-82E3-88ED7BD13C1B

P407

Q24628845-D0032FC3-A89E-407D-B760-E8893FA83893

P433

Q24628845-BCA0A90B-465B-42E4-A4F8-BAA8F2FB1063

P478

Q24628845-6A3F2777-26E4-4A03-B0D9-B2F61240CEBB

P577

Q24628845-FCD13DE6-55B3-4C6E-BF29-430657423BDC

P5875

Q24628845-78DA7127-5326-4F73-94C6-886414B3F51C

P698

Q24628845-2AE0E784-A8DB-4C7D-BEC7-3855EFD9E45F

P932

Q24628845-B9C9DDDA-BAD2-4040-A40B-572DE4606AC4

P3181

P356

SCIENCE.1217697

P1433

P1476

ApoE-directed therapeutics rap ...... se deficits in AD mouse models

@en

P2093

Adriana E Zinn

http://www.w3.org/2001/XMLSchema#string

Brad T Casali

http://www.w3.org/2001/XMLSchema#string

C Y Daniel Lee

http://www.w3.org/2001/XMLSchema#string

Daniel W Wesson

http://www.w3.org/2001/XMLSchema#string

Donald A Wilson

http://www.w3.org/2001/XMLSchema#string

Gary E Landreth

http://www.w3.org/2001/XMLSchema#string

J Colleen Karlo

http://www.w3.org/2001/XMLSchema#string

Jessica L Restivo

http://www.w3.org/2001/XMLSchema#string

John R Cirrito

http://www.w3.org/2001/XMLSchema#string

Kurt R Brunden

http://www.w3.org/2001/XMLSchema#string

P2860

Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

Alzheimer's Disease

Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks

ApoE promotes the proteolytic degradation of Abeta

Analyzing real-time PCR data by the comparative C(T) method

A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis

Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease

Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.

Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease

P304

1503-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

397916

http://www.w3.org/2001/XMLSchema#string

P356

10.1126/SCIENCE.1217697

http://www.w3.org/2001/XMLSchema#string

P407

P433

6075

http://www.w3.org/2001/XMLSchema#string

P478

335

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221822232

http://www.w3.org/2001/XMLSchema#string

P698

22323736

http://www.w3.org/2001/XMLSchema#string

P932

3651582

http://www.w3.org/2001/XMLSchema#string